Logo image of IDRA

IDERA PHARMACEUTICALS INC (IDRA) Stock Fundamental Analysis

USA - NASDAQ:IDRA - US45168K4058 - Common Stock

0.425 USD
-0.12 (-21.57%)
Last: 1/17/2023, 8:00:02 PM
0.42 USD
-0.01 (-1.18%)
After Hours: 1/17/2023, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, IDRA scores 2 out of 10 in our fundamental rating. IDRA was compared to 534 industry peers in the Biotechnology industry. While IDRA seems to be doing ok healthwise, there are quite some concerns on its profitability. IDRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IDRA was profitable.
In the past year IDRA has reported a negative cash flow from operations.
IDRA Yearly Net Income VS EBIT VS OCF VS FCFIDRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M -100M

1.2 Ratios

IDRA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IDRA Yearly ROA, ROE, ROICIDRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 -200 400 600

1.3 Margins

IDRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDRA Yearly Profit, Operating, Gross MarginsIDRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, IDRA has more shares outstanding
IDRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IDRA Yearly Shares OutstandingIDRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
IDRA Yearly Total Debt VS Total AssetsIDRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

IDRA has an Altman-Z score of -10.25. This is a bad value and indicates that IDRA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.25, IDRA is not doing good in the industry: 81.53% of the companies in the same industry are doing better.
IDRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.25
ROIC/WACCN/A
WACCN/A
IDRA Yearly LT Debt VS Equity VS FCFIDRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

IDRA has a Current Ratio of 1.56. This is a normal value and indicates that IDRA is financially healthy and should not expect problems in meeting its short term obligations.
IDRA's Current ratio of 1.56 is on the low side compared to the rest of the industry. IDRA is outperformed by 86.23% of its industry peers.
IDRA has a Quick Ratio of 1.56. This is a normal value and indicates that IDRA is financially healthy and should not expect problems in meeting its short term obligations.
IDRA has a worse Quick ratio (1.56) than 85.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.56
IDRA Yearly Current Assets VS Current LiabilitesIDRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

IDRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 160.78%, which is quite impressive.
EPS 1Y (TTM)160.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IDRA Yearly Revenue VS EstimatesIDRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 5M 10M 15M
IDRA Yearly EPS VS EstimatesIDRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.18, which indicates a rather cheap valuation of IDRA.
Based on the Price/Earnings ratio, IDRA is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of IDRA to the average of the S&P500 Index (26.91), we can say IDRA is valued rather cheaply.
Industry RankSector Rank
PE 0.18
Fwd PE N/A
IDRA Price Earnings VS Forward Price EarningsIDRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDRA Per share dataIDRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IDRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDERA PHARMACEUTICALS INC

NASDAQ:IDRA (1/17/2023, 8:00:02 PM)

After market: 0.42 -0.01 (-1.18%)

0.425

-0.12 (-21.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-29 2023-03-29
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners11.98%
Ins Owner Change0%
Market Cap25.08M
Revenue(TTM)N/A
Net Income(TTM)-17853000
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.18
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB N/A
EV/EBITDA N/A
EPS(TTM)2.34
EY550.59%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS0.85
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.56
Quick Ratio 1.56
Altman-Z -10.25
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)8.33%
Cap/Depr(5y)14.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)160.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.99%
OCF growth 3YN/A
OCF growth 5YN/A

IDERA PHARMACEUTICALS INC / IDRA FAQ

What is the ChartMill fundamental rating of IDERA PHARMACEUTICALS INC (IDRA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IDRA.


Can you provide the valuation status for IDERA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 9 / 10 to IDERA PHARMACEUTICALS INC (IDRA). This can be considered as Undervalued.


How profitable is IDERA PHARMACEUTICALS INC (IDRA) stock?

IDERA PHARMACEUTICALS INC (IDRA) has a profitability rating of 1 / 10.


How financially healthy is IDERA PHARMACEUTICALS INC?

The financial health rating of IDERA PHARMACEUTICALS INC (IDRA) is 2 / 10.